Reneo Pharmaceuticals (RPHM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

RPHM Stock Forecast


Reneo Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

RPHM Analyst Ratings


Buy

According to 1 Wall Street analysts, Reneo Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RPHM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 17, 2022Piper SandlerOverweightOverweightHold
Row per page
Go to

Reneo Pharmaceuticals's last stock rating was published by Piper Sandler on May 17, 2022. The company gave RPHM a "Overweight" rating, the same as its previous rate.

Reneo Pharmaceuticals Financial Forecast


Reneo Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast$15.96M$7.97M--$100.25K$27.25K-
High Forecast$15.96M$7.97M--$100.25K$27.25K-
Low Forecast$15.96M$7.97M--$100.25K$27.25K-
# Analysts11--11-
Surprise %-------

Reneo Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RPHM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Reneo Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11--11-
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict RPHM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Reneo Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Reneo Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11--11-
Net Income-------
Avg Forecast$-6.35M$-10.34M$-16.82M$-18.83M$-2.34M$-2.34M$-3.34M
High Forecast$-6.35M$-10.34M$-16.82M$-18.83M$-2.34M$-2.34M$-3.34M
Low Forecast$-6.35M$-10.34M$-16.82M$-18.83M$-2.34M$-2.34M$-3.34M
Surprise %-------

Reneo Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RPHM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Reneo Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11--11-
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Reneo Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RPHM last annual SG&A of $NaN (undefined).

Reneo Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11--11-
EPS-------
Avg Forecast$-0.19$-0.31$-0.50$-0.56$-0.07$-0.07$-0.10
High Forecast$-0.19$-0.31$-0.50$-0.56$-0.07$-0.07$-0.10
Low Forecast$-0.19$-0.31$-0.50$-0.56$-0.07$-0.07$-0.10
Surprise %-------

According to undefined Wall Street analysts, Reneo Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RPHM previous annual EPS of $NaN (undefined).

Reneo Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.63$70.0011011.11%Buy
KRONKronos Bio$0.95$7.63703.16%Buy
NKTXNkarta$3.23$21.60568.73%Buy
HOWLWerewolf Therapeutics$2.26$12.00430.97%Buy
CNSPCNS Pharmaceuticals$0.11$0.50354.55%-
IMMXImmix Biopharma$1.58$7.00343.04%Buy
PRMEPrime Medicine$3.96$17.25335.61%Buy
VIRVir Bio$9.37$26.60183.88%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
KZRKezar Life Sciences$7.09$17.50146.83%Buy
ADPTAdaptive Bio$5.26$12.33134.41%Hold
CCCCC4 Therapeutics$6.45$13.50109.30%Buy
CELCCelcuity$15.36$31.50105.08%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
LEGNLegend Biotech$43.61$82.6289.45%Buy
SMMTSummit Therapeutics$19.96$36.0080.36%Buy
RPRXRoyalty Pharma$27.20$43.3359.30%Buy
EWTXEdgewise Therapeutics$34.48$45.0030.51%Buy
RPHMReneo Pharmaceuticals$18.20$18.00-1.10%Buy
DNAGinkgo Bioworks$7.63$7.34-3.80%Buy

RPHM Forecast FAQ


Yes, according to 1 Wall Street analysts, Reneo Pharmaceuticals (RPHM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RPHM's total ratings.

Reneo Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $127.5K (high $127.5K, low $127.5K), average EBITDA is $0 (high $0, low $0), average net income is $-8.021M (high $-8.021M, low $-8.021M), average SG&A $0 (high $0, low $0), and average EPS is $-0.24 (high $-0.24, low $-0.24). RPHM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.93M (high $23.93M, low $23.93M), average EBITDA is $0 (high $0, low $0), average net income is $-52.334M (high $-52.334M, low $-52.334M), average SG&A $0 (high $0, low $0), and average EPS is $-1.566 (high $-1.566, low $-1.566).